サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：アダリムマブの世界市場 (～2028年)：タイプ・製品タイプ・治療領域・流通チャネル・エンドユーザー・地域別の産業規模・シェア・動向・機会・予測
市場調査レポート
商品コード
1174488

アダリムマブの世界市場 (～2028年)：タイプ・製品タイプ・治療領域・流通チャネル・エンドユーザー・地域別の産業規模・シェア・動向・機会・予測

Adalimumab Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Type, By Product Type, By Therapeutic Area, By Distribution Channel, By End Users, By Region, Forecast & Opportunities, 2028
出版日: | 発行: TechSci Research | ページ情報: 英文 116 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円

こちらのレポートには、数時間（ご購入金額の10%）分のアナリストへの質問／追加調査サービスが含まれております。

アダリムマブの世界市場 (～2028年)：タイプ・製品タイプ・治療領域・流通チャネル・エンドユーザー・地域別の産業規模・シェア・動向・機会・予測
出版日: 2022年12月01日
発行: TechSci Research
ページ情報: 英文 116 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 目次
概要

世界のアダリムマブの市場は2024年から2028年にかけて大きな成長を遂げると予想されています。

関節炎の有病率の上昇と多数の臨床試験の実施が同市場の成長に拍車をかけています。また、保険償還の範囲や明確な規制ガイドラインも2028年にかけての市場成長に拍車をかけると予想されています。一方で、ブロックバスター薬の特許満了や副反応が市場成長を抑制すると予想されています。

当レポートでは、世界のアダリムマブの市場を調査し、市場概要、市場規模および市場シェアの推移・予測、各種区分・地域/主要国別の詳細分析、市場への各種影響因子の分析、競合環境、主要企業のプロファイルなどをまとめています。

目次

第1章 製品概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 VOC (顧客の声)

第5章 アダリムマブの薬力学的概要

  • 作用機序
  • 吸収
  • 流通量
  • 排泄経路
  • 半減期
  • クリアランス
  • 毒性

第6章 臨床試験

  • 進行中の臨床試験
  • 完了臨床試験
  • 中止臨床試験
  • 臨床試験分析

第7章 特許分析

第8章 世界のアダリムマブ市場の展望

  • 市場規模・予測
  • 市場シェア・予測
    • タイプ別 (生物製剤・バイオシミラー)
    • 製品タイプ別 (ブランド・ジェネリック)
    • 治療領域別 (関節リウマチ・乾癬性関節炎・乾癬・クローン病・その他)
    • 流通チャネル (病院薬局・小売薬局・オンライン薬局・その他)
    • エンドユーザー別 (病院および診療所・在宅医療・その他)
    • 企業別 (2022年)
    • 地域別
  • 製品市場マップ

第9章 北米のアダリムマブ市場の展望

  • 市場規模・予測
  • 市場シェア・予測
    • タイプ別
    • 製品タイプ別
    • 治療領域別
    • 流通チャネル別
    • エンドユーザー別
    • 国別
  • 国別分析

第10章 欧州のアダリムマブ市場の展望

  • 市場規模・予測
  • 市場シェア・予測
    • タイプ別
    • 製品タイプ別
    • 治療領域別
    • 流通チャネル別
    • エンドユーザー別
    • 国別
  • 国別分析

第11章 アジア太平洋のアダリムマブ市場の展望

  • 市場規模・予測
  • 市場シェア・予測
    • タイプ別
    • 製品タイプ別
    • 治療領域別
    • 流通チャネル別
    • エンドユーザー別
    • 国別
  • 国別分析

第12章 南米のアダリムマブ市場の展望

  • 市場規模・予測
  • 市場シェア・予測
    • タイプ別
    • 製品タイプ別
    • 治療領域別
    • 流通チャネル別
    • エンドユーザー別
    • 国別
  • 国別分析

第13章 中東・アフリカのアダリムマブ市場の展望

  • 市場規模・予測
  • 市場シェア・予測
    • タイプ別
    • 製品タイプ別
    • 治療領域別
    • 流通チャネル別
    • エンドユーザー別
    • 国別
  • 国別分析

第14章 市場力学

  • 促進要因
  • 課題

第15章 市場の動向・展開

第16章 競合情勢

  • Abbvie Inc.
  • Pfizer, Inc.
  • Amgen Inc.
  • Novartis AG
  • Torrent Pharmaceuticals Ltd.
  • Cadila Healthcare Limited
  • Boehringer Ingelheim International GmbH
  • Mylan N.V.
  • Hetero Biopharma Ltd
  • Samsung Bioepis Co Ltd.

第17章 戦略的提言

第18章 当社について・免責事項

目次
Product Code: 4996

Global adalimumab market is expected to undergo significant growth during the forecast period, 2024-2028. The rising prevalence of arthritis coupled with large number of clinical trials is impelling the growth of the market. Adalimumab is an anti-TNF drug which is used for the treatment of rheumatoid arthritis, psoriatic arthritis, psoriasis and ulcerative colitis. Adalimumab lowers the chances of inflammatory response by binding to a TNFα. Adalimumab are currently being marketed in over 60 countries around the world.

Several companies are undergoing extensive clinical trials and R&D activities, which in turn, is expected to augment a major growth factor for global adalimumab market. The reimbursement coverage and well-defined regulatory guidelines are further expected to fuel the market growth through 2028. However, patent expiration of blockbuster drugs is expected to slow down the market growth. Besides, side effects associated with the drugs is expected to restrain the growth of the market.

Global adalimumab market is segmented based on based on type, product type, therapeutic area, distribution channel, end user, company and region. Based on therapeutic area, the market is categorized into rheumatoid arthritis, psoriatic arthritis, psoriasis, Crohn's disease, and others. Among them, the rheumatoid arthritis is expected to dominate the global market owing to high prevalence among elderly population.

Regionally, North America is expected to dominate the global adalimumab market followed by Europe. The advanced healthcare infrastructure and well-organized regulatory framework in these two regions is making them a lucrative market for adalimumab manufacturers.

Major companies operating in global adalimumab market include Abbvie Inc., Pfizer Inc., Amgen Inc., Novartis AG, Torrent Pharmaceuticals Ltd., Cadila Healthcare Ltd, Boehringer Ingelheim International GmbH, Mylan N.V., Hetero Biopharma Ltd., and Samsung Bioepis Co Ltd. The market players are undergoing extensive clinical trials to test the safety and efficacy of the adalimumab in treatment of various diseases.

Objective of the Study

  • To analyse and forecast the market size of global adalimumab market.
  • To forecast global adalimumab market based on based on type, product type, therapeutic area, distribution channel, end user, company and region.
  • To identify drivers and challenges for global adalimumab market.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions etc. in global adalimumab market.
  • To identify and analyse the profile of leading players operating in the global adalimumab market.

TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of adalimumab manufacturing companies across the globe. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the companies which could not be identified due to the limitations of secondary research.

TechSci Research calculated global adalimumab market size using a bottom-up approach, where data for various end user industries and its application across various product types were recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analysing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also used by TechSci Research.

Key Target Audience:

  • Adalimumab manufacturers, companies, partners, hospitals pharmacy/retail pharmacy and other stakeholders
  • Government bodies such as regulating authorities and policy makers
  • Organizations, industry associations, forums and alliances related to adalimumab
  • Market research and consulting firms

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as adalimumab manufacturing companies, end users etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope

In this report, global adalimumab market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Global Adalimumab Market, By Type:

  • Biologics
  • Biosimilar

Global Adalimumab Market, By Product Type:

  • Branded
  • Generics

Global Adalimumab Market, By Therapeutic Area:

  • Rheumatoid Arthritis
  • Psoriatic Arthritis
  • Psoriasis
  • Crohn's Disease
  • Others

Global Adalimumab Market, By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

Global Adalimumab Market, By End User:

  • Hospitals & Clinics
  • Home Healthcare
  • Others

Global Adalimumab Market, By Region:

  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
  • Europe
    • France
    • Germany
    • United Kingdom
    • Italy
    • Spain
  • North America
    • United States
    • Mexico
    • Canada
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global adalimumab market.

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Profit Margin Analysis

  • Profit margin analysis in case of direct and indirect sales channel.

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

  • 4.1. Adalimumab Demand, By Therapeutic Area
  • 4.2. Adalimumab Demand, By Region
  • 4.3. Adalimumab Demand, By Gender
  • 4.4. Adalimumab Demand, By Patient Population
  • 4.5. Commonly Observed Side-Effects
  • 4.6. Brand Awareness

5. Pharmacodynamic Overview of Adalimumab

  • 5.1. Mechanism of Action
  • 5.2. Absorption
  • 5.3. Volume of Distribution
  • 5.4. Route of Elimination
  • 5.5. Half Life
  • 5.6. Clearance
  • 5.7. Toxicity

6. Clinical Trials

  • 6.1. Ongoing Clinical Trials
  • 6.2. Completed Clinical Trials
  • 6.3. Terminated Clinical Trials
  • 6.4. Clinical Trial Analysis

7. Patent Analysis

  • 7.1. Patent Granted
  • 7.2. Patent Applications Filed

8. Global Adalimumab Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type (Biologics v/s Biosimilars)
    • 8.2.2. By Product Type (Branded v/s Generics)
    • 8.2.3. By Therapeutic Area (Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis, Crohn's Disease, Others)
    • 8.2.4. Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others)
    • 8.2.5. By End User (Hospitals & Clinics, Home Healthcare, Others)
    • 8.2.6. By Company (2022)
    • 8.2.7. By Region
  • 8.3. Product Market Map

9. North America Adalimumab Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value & Volume
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Product Type
    • 9.2.3. By Therapeutic Area
    • 9.2.4. By Distribution Channel
    • 9.2.5. By End User
    • 9.2.6. By Country
  • 9.3. North America: Country Analysis
    • 9.3.1. United States Adalimumab Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Product Type
        • 9.3.1.2.3. By Therapeutic Area
        • 9.3.1.2.4. By Distribution Channel
        • 9.3.1.2.5. By End User
    • 9.3.2. Mexico Adalimumab Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Product Type
        • 9.3.2.2.3. By Therapeutic Area
        • 9.3.2.2.4. By Distribution Channel
        • 9.3.2.2.5. By End User
    • 9.3.3. Canada Adalimumab Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Product Type
        • 9.3.3.2.3. By Therapeutic Area
        • 9.3.3.2.4. By Distribution Channel
        • 9.3.3.2.5. By End User

10. Europe Adalimumab Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value & Volume
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Product Type
    • 10.2.3. By Therapeutic Area
    • 10.2.4. By Distribution Channel
    • 10.2.5. By End User
    • 10.2.6. By Country
  • 10.3. Europe: Country Analysis
    • 10.3.1. France Adalimumab Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Product Type
        • 10.3.1.2.3. By Therapeutic Area
        • 10.3.1.2.4. By Distribution Channel
        • 10.3.1.2.5. By End User
    • 10.3.2. Germany Adalimumab Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Product Type
        • 10.3.2.2.3. By Therapeutic Area
        • 10.3.2.2.4. By Distribution Channel
        • 10.3.2.2.5. By End User
    • 10.3.3. United Kingdom Adalimumab Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Product Type
        • 10.3.3.2.3. By Therapeutic Area
        • 10.3.3.2.4. By Distribution Channel
        • 10.3.3.2.5. By End User
    • 10.3.4. Italy Adalimumab Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Type
        • 10.3.4.2.2. By Product Type
        • 10.3.4.2.3. By Therapeutic Area
        • 10.3.4.2.4. By Distribution Channel
        • 10.3.4.2.5. By End User
    • 10.3.5. Spain Adalimumab Market Outlook
      • 10.3.5.1. Market Size & Forecast
        • 10.3.5.1.1. By Value
      • 10.3.5.2. Market Share & Forecast
        • 10.3.5.2.1. By Type
        • 10.3.5.2.2. By Product Type
        • 10.3.5.2.3. By Therapeutic Area
        • 10.3.5.2.4. By Distribution Channel
        • 10.3.5.2.5. By End User

11. Asia-Pacific Adalimumab Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value & Volume
  • 11.2. Market Share & Forecast
    • 11.2.1. By Type
    • 11.2.2. By Product Type
    • 11.2.3. By Therapeutic Area
    • 11.2.4. By Distribution Channel
    • 11.2.5. By End User
    • 11.2.6. By Country
  • 11.3. Asia-Pacific: Country Analysis
    • 11.3.1. China Adalimumab Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Type
        • 11.3.1.2.2. By Product Type
        • 11.3.1.2.3. By Therapeutic Area
        • 11.3.1.2.4. By Distribution Channel
        • 11.3.1.2.5. By End User
    • 11.3.2. India Adalimumab Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Type
        • 11.3.2.2.2. By Product Type
        • 11.3.2.2.3. By Therapeutic Area
        • 11.3.2.2.4. By Distribution Channel
        • 11.3.2.2.5. By End User
    • 11.3.3. South Korea Adalimumab Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Transgenic Crop
        • 11.3.3.2.2. By Technique
        • 11.3.3.2.3. By Application
        • 11.3.3.2.4. By End User
    • 11.3.4. Japan Adalimumab Market Outlook
      • 11.3.4.1. Market Size & Forecast
        • 11.3.4.1.1. By Value
      • 11.3.4.2. Market Share & Forecast
        • 11.3.4.2.1. By Type
        • 11.3.4.2.2. By Product Type
        • 11.3.4.2.3. By Therapeutic Area
        • 11.3.4.2.4. By Distribution Channel
        • 11.3.4.2.5. By End User
    • 11.3.5. Australia Adalimumab Market Outlook
      • 11.3.5.1. Market Size & Forecast
        • 11.3.5.1.1. By Value
      • 11.3.5.2. Market Share & Forecast
        • 11.3.5.2.1. By Type
        • 11.3.5.2.2. By Product Type
        • 11.3.5.2.3. By Therapeutic Area
        • 11.3.5.2.4. By Distribution Channel
        • 11.3.5.2.5. By End User

12. South America Adalimumab Market Outlook

  • 12.1. Market Size & Forecast
    • 12.1.1. By Value & Volume
  • 12.2. Market Share & Forecast
    • 12.2.1. By Type
    • 12.2.2. By Product Type
    • 12.2.3. By Therapeutic Area
    • 12.2.4. By Distribution Channel
    • 12.2.5. By End User
    • 12.2.6. By Country
  • 12.3. South America: Country Analysis
    • 12.3.1. Brazil Adalimumab Market Outlook
      • 12.3.1.1. Market Size & Forecast
        • 12.3.1.1.1. By Value
      • 12.3.1.2. Market Share & Forecast
        • 12.3.1.2.1. By Type
        • 12.3.1.2.2. By Product Type
        • 12.3.1.2.3. By Therapeutic Area
        • 12.3.1.2.4. By Distribution Channel
        • 12.3.1.2.5. By End User
    • 12.3.2. Argentina Adalimumab Market Outlook
      • 12.3.2.1. Market Size & Forecast
        • 12.3.2.1.1. By Value
      • 12.3.2.2. Market Share & Forecast
        • 12.3.2.2.1. By Type
        • 12.3.2.2.2. By Product Type
        • 12.3.2.2.3. By Therapeutic Area
        • 12.3.2.2.4. By Distribution Channel
        • 12.3.2.2.5. By End User
    • 12.3.3. Colombia Adalimumab Market Outlook
      • 12.3.3.1. Market Size & Forecast
        • 12.3.3.1.1. By Value
      • 12.3.3.2. Market Share & Forecast
        • 12.3.3.2.1. By Type
        • 12.3.3.2.2. By Product Type
        • 12.3.3.2.3. By Therapeutic Area
        • 12.3.3.2.4. By Distribution Channel
        • 12.3.3.2.5. By End User

13. Middle East and Africa Adalimumab Market Outlook

  • 13.1. Market Size & Forecast
    • 13.1.1. By Value & Volume
  • 13.2. Market Share & Forecast
    • 13.2.1. By Type
    • 13.2.2. By Product Type
    • 13.2.3. By Therapeutic Area
    • 13.2.4. By Distribution Channel
    • 13.2.5. By End User
    • 13.2.6. By Country
  • 13.3. MEA: Country Analysis
    • 13.3.1. South Africa Adalimumab Market Outlook
      • 13.3.1.1. Market Size & Forecast
        • 13.3.1.1.1. By Value
      • 13.3.1.2. Market Share & Forecast
        • 13.3.1.2.1. By Type
        • 13.3.1.2.2. By Product Type
        • 13.3.1.2.3. By Therapeutic Area
        • 13.3.1.2.4. By Distribution Channel
        • 13.3.1.2.5. By End User
    • 13.3.2. Saudi Arabia Adalimumab Market Outlook
      • 13.3.2.1. Market Size & Forecast
        • 13.3.2.1.1. By Value
      • 13.3.2.2. Market Share & Forecast
        • 13.3.2.2.1. By Type
        • 13.3.2.2.2. By Product Type
        • 13.3.2.2.3. By Therapeutic Area
        • 13.3.2.2.4. By Distribution Channel
        • 13.3.2.2.5. By End User
    • 13.3.3. UAE Adalimumab Market Outlook
      • 13.3.3.1. Market Size & Forecast
        • 13.3.3.1.1. By Value
      • 13.3.3.2. Market Share & Forecast
        • 13.3.3.2.1. By Type
        • 13.3.3.2.2. By Product Type
        • 13.3.3.2.3. By Therapeutic Area
        • 13.3.3.2.4. By Distribution Channel
        • 13.3.3.2.5. By End User

14. Market Dynamics

  • 14.1. Drivers
  • 14.2. Challenges

15. Market Trends & Developments

16. Competitive Landscape

  • 16.1. Abbvie Inc.
  • 16.2. Pfizer, Inc.
  • 16.3. Amgen Inc.
  • 16.4. Novartis AG
  • 16.5. Torrent Pharmaceuticals Ltd.
  • 16.6. Cadila Healthcare Limited
  • 16.7. Boehringer Ingelheim International GmbH
  • 16.8. Mylan N.V.
  • 16.9. Hetero Biopharma Ltd
  • 16.10. Samsung Bioepis Co Ltd.

17. Strategic Recommendations

18. About Us & Disclaimer